These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
995 related articles for article (PubMed ID: 6355296)
41. Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway. Zhang MX; Kozel TR Infect Immun; 1998 Oct; 66(10):4845-50. PubMed ID: 9746588 [TBL] [Abstract][Full Text] [Related]
42. Sub-minimal inhibitory concentrations of cefmetazole enhance serum bactericidal activity in vitro by amplifying poly-C9 deposition. Schweinle JE; Nishiyasu M J Clin Invest; 1992 Apr; 89(4):1198-207. PubMed ID: 1556181 [TBL] [Abstract][Full Text] [Related]
43. Supplemental complement component C9 enhances the capacity of neonatal serum to kill multiple isolates of pathogenic Escherichia coli. Lassiter HA; Wilson JL; Feldhoff RC; Hoffpauir JM; Klueber KM Pediatr Res; 1994 Apr; 35(4 Pt 1):389-96. PubMed ID: 8047374 [TBL] [Abstract][Full Text] [Related]
44. Interaction of turkey complement with Escherichia coli isolated from turkeys. Ellis MG; Arp LH; Lamont SJ Am J Vet Res; 1989 Aug; 50(8):1285-9. PubMed ID: 2675694 [TBL] [Abstract][Full Text] [Related]
45. Requirement of extracellular complement and immunoglobulin for intracellular killing of micro-organisms by human monocytes. Leijh PC; van den Barselaar MT; van Zwet TL; Daha MR; van Furth R J Clin Invest; 1979 Apr; 63(4):772-84. PubMed ID: 374424 [TBL] [Abstract][Full Text] [Related]
46. Characterization of complement resistance in Escherichia coli conferred by the antibiotic resistance plasmid R100. Ogata RT; Levine RP J Immunol; 1980 Oct; 125(4):1494-8. PubMed ID: 6997381 [TBL] [Abstract][Full Text] [Related]
47. The requirement of specific antibody for the killing of E. coli by the alternate complement pathway in bovine serum. Hill AW; Shears AL; Hibbitt KG Immunology; 1978 Jan; 34(1):131-6. PubMed ID: 75177 [TBL] [Abstract][Full Text] [Related]
48. Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule. Pausa M; Pellis V; Cinco M; Giulianini PG; Presani G; Perticarari S; Murgia R; Tedesco F J Immunol; 2003 Mar; 170(6):3214-22. PubMed ID: 12626580 [TBL] [Abstract][Full Text] [Related]
50. Regulation of complement activation at the C3-level by serum resistant leptospires. Meri T; Murgia R; Stefanel P; Meri S; Cinco M Microb Pathog; 2005 Oct; 39(4):139-47. PubMed ID: 16169184 [TBL] [Abstract][Full Text] [Related]
51. Antibody-dependent cell-mediated cytotoxicity- and complement-dependent cytotoxicity-independent bactericidal activity of an IgG against Pseudomonas aeruginosa O6ad. Xie X; McLean MD; Hall JC J Immunol; 2010 Apr; 184(7):3725-33. PubMed ID: 20190144 [TBL] [Abstract][Full Text] [Related]
52. The effect of specific antibody on antibody-independent interactions between E. coli J5 and human complement. Betz SJ; Page N; Estrade C; Isliker H J Immunol; 1982 Feb; 128(2):707-11. PubMed ID: 7033382 [TBL] [Abstract][Full Text] [Related]
53. Independent effects of IgG and complement upon human polymorphonuclear leukocyte function. Goldstein IM; Kaplan HB; Radin A; Frosch M J Immunol; 1976 Oct; 117(4):1282-7. PubMed ID: 185296 [TBL] [Abstract][Full Text] [Related]
54. Further studies on the biologic properties of guinea pig IgG1 antibodies. II. In vivo activation of C3 by anti-glomerular basement membrane antibodies. Vuagnat P J Immunol; 1975 Sep; 115(3):787-95. PubMed ID: 50374 [TBL] [Abstract][Full Text] [Related]
55. Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9. Joiner KA; Schmetz MA; Sanders ME; Murray TG; Hammer CH; Dourmashkin R; Frank MM Proc Natl Acad Sci U S A; 1985 Jul; 82(14):4808-12. PubMed ID: 3895225 [TBL] [Abstract][Full Text] [Related]
56. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates. Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130 [TBL] [Abstract][Full Text] [Related]
57. Complement-mediated serum cytotoxicity for Leishmania major amastigotes: killing by serum deficient in early components of the membrane attack complex. Hoover DL; Berger M; Hammer CH; Meltzer MS J Immunol; 1985 Jul; 135(1):570-4. PubMed ID: 3998474 [TBL] [Abstract][Full Text] [Related]
58. Surface-bound capsular polysaccharide of type Ia group B Streptococcus mediates C1 binding and activation of the classic complement pathway. Levy NJ; Kasper DL J Immunol; 1986 Jun; 136(11):4157-62. PubMed ID: 3517165 [TBL] [Abstract][Full Text] [Related]
59. Further studies of the adjuvant properties of homologous IgG split products: mode of action of F(ab')2 and related fragments. Kulberg AJ; Bartova LM; Evnin DN Immunology; 1978 Feb; 34(2):199-206. PubMed ID: 342398 [TBL] [Abstract][Full Text] [Related]
60. Evasion of the alternative complement pathway by metacyclic trypomastigotes of Trypanosoma cruzi: dependence on the developmentally regulated synthesis of surface protein and N-linked carbohydrate. Sher A; Hieny S; Joiner K J Immunol; 1986 Nov; 137(9):2961-7. PubMed ID: 3531342 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]